Abstracts tagged "patient outcomes"

Abstract Number: 854 • 2016 ACR/ARHP Annual Meeting
The Ducas: Proposal for a Digital Ulcer Assessment Score in Scleroderma
Cosimo Bruni¹, Tanaka Ngcozana², Francesca Braschi³, Guya Piemonte⁴, Laura Benelli⁴, Serena Guiducci⁵, Silvia Bellando-Randone³, Jonathan Grotts⁶, Christopher Denton⁷, Daniel E. Furst⁸ and Marco Matucci-Cerinic⁵, ¹Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ²Rheumatology Department, Lower, Royal Free hospital, London, United Kingdom, ³Department of Clinical and Experimental Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ⁴University of Florence, Florence, Italy, ⁵Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁶Biostatistics, University of California Los Angeles, Los Angeles, CA, ⁷Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁸Division of Rheumatology, Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: No objective measure is presently available to assess digital ulcer (DU) in SSc patients apart from “healed/non healed” and experience-based clinical judgment. The aim…
Abstract Number: 2750 • 2016 ACR/ARHP Annual Meeting
Concordance Between Patient and Physician Global Assessment of the Disease in Patients with Psoriatic Arthritis
Josefina Gallino Yanzi¹, Osvaldo Luis Cerda², Margarita Landi², Cecilia Zaffarana², Emilce Schneeberger² and Gustavo Citera¹, ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: In Rheumatoid Arthritis it has been observed a significant discrepancy in the global assessment of the disease by the patient and physician and this…
Abstract Number: 889 • 2016 ACR/ARHP Annual Meeting
The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², Gunnar Tomasson³, Joshua F. Baker⁴, David Cuthbertson⁵, Renee Borchin⁶, Simon Carette⁷, Lindsy J. Forbess⁸, Gary S. Hoffman⁹, Nader A. Khalidi¹⁰, Curry L. Koening¹¹, Carol A. McAlear¹², Paul A. Monach¹³, Larry W. Moreland¹⁴, Christian Pagnoux¹⁵, Philip Seo¹⁶, Robert F. Spiera¹⁷, Kenneth J. Warrington¹⁸, Steven R. Ytterberg², Carol A. Langford¹⁹ and Peter A. Merkel²⁰, ¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁶University of South Florida, Tampa, FL, ⁷Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁰Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ¹¹Rheumatology, University of Utah, Salt Lake City, UT, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ¹⁶Medicine, Johns Hopkins University, Baltimore, MD, ¹⁷Hospital for Special Surgery, Cornell, New York, NY, ¹⁸Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, ¹⁹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²⁰Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: Takayasu’s arteritis (TAK) is a relapsing large vessel vasculitis. There are currently no reliable predictors of disease relapse. This study explored whether changes in…
Abstract Number: 3179 • 2016 ACR/ARHP Annual Meeting
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Joanna C. Robson^1,2,3, Jill Dawson⁴, Judy A. Shea⁵, Helen Doll⁶, Susan Ashdown⁷, Renee Borchin⁸, Ebony Easley⁹, John T. Farrar¹⁰, Don Gebhart¹¹, Katherine Kellom¹², Georgia Lanier¹³, Raashid Luqmani¹⁴, Carol A McAlear¹⁵, John Mills¹⁶, Nataliya Milman^17,18,19, Jacqueline Peck⁷, Gunnar Tomasson²⁰, Peter F. Cronholm⁹ and Peter A. Merkel²¹, ¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ²Department of Rheumatology, University Hospitals Bristol NHS Trust, Bristol, United Kingdom, ³School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ⁴Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁵Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Department of Population Health, University of East Anglia, Norwich, United Kingdom, ⁷Oxford, Oxford, United Kingdom, ⁸University of South Florida, Tampa, FL, ⁹Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Columbus, Columbus, OH, ¹²PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ¹³NONE, Framingham, MA, ¹⁴NDORMS , Rheumathology, Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁵Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Vasculitis UK, Sheffield, United Kingdom, ¹⁷Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ¹⁸The Ottawa Hospital, Ottawa, ON, Canada, ¹⁹Department of Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²⁰Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, ²¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and…
Abstract Number: 890 • 2016 ACR/ARHP Annual Meeting
Health-Related Domains of Importance to Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Fatma Alibaz-Oner², Ebony Easley³, Trocon Davis³, Gonca Mumcu⁴, Nataliya Milman⁵, Joanna C. Robson⁶, Peter F. Cronholm³, Haner Direskeneli⁷ and Peter A. Merkel⁸, ¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁴Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁵Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ⁶Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: The need to include patients’ perspectives as key outcomes in clinical research is now widely recognized. This project was designed to describe the experience…
Abstract Number: 1306 • 2016 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Measures of Disease Activity in Rheumatoid Arthritis Patients Treated with Multiple Regimens of DMARD Therapy
Paolo Pace¹, Arthur Lau², Jonathan D. Adachi³, Matthew A. Jessome⁴, George Ioannidis² and Minta Patel⁵, ¹Rheumatology, McMaster Unversity, Hamilton, ON, Canada, ²St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada, ⁵Cambridge Memorial Hospital, Cambridge, ON, Canada
Background/Purpose: Magnetic resonance imaging ( MRI ) in rheumatoid arthritis ( RA ) has been shown to be more sensitive than clinical and radiological parameters…
Abstract Number: 1423 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis
Stephen Doogan¹, John Heid², Samir Benosman³, Alexis Ogdie⁴, Layne Martin⁵, Prashanth Sunkureddi⁶ and Jacqueline Palmer⁷, ¹Real Life Sciences, New York, NY, ²Kinapse, Inc, London, United Kingdom, ³Advisory Services, Kinapse, Inc, London, United Kingdom, ⁴University of Pennsylvania, Philadelphia, PA, ⁵CreakyJoints, NY, ⁶Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a debilitating disease with significant impact on patient quality of life (QoL). While patient reported outcome (PRO) instruments broadly capture…
Abstract Number: 1426 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis
Prashanth Sunkureddi¹, Dawn Gibson², Stephen Doogan³, John Heid⁴, Samir Benosman⁵ and Yujin Park⁶, ¹Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ²The Global Healthy Living Foundation, Upper Nyack, NY, ³Real Life Sciences, New York, NY, ⁴Kinapse, Inc, London, United Kingdom, ⁵Advisory Services, Kinapse, Inc, London, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the spinal joints that can lead to severe, chronic pain and discomfort. There is a…
Abstract Number: 2667 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Health Outcomes of RA Patients Not Adequately Controlled By Current Treatment
Peter C. Taylor¹, Rieke Alten², Philippe Bertin³, Roberto Caporali⁴, Juan J Gomez-Reino⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Rheumatology, CHU Dupuytren, Limoges, France, ⁴University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁵Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: Despite an increasing armamentarium of efficacious treatments for Rheumatoid Arthritis (RA), sustained remission remains an unrealistic expectation for many patients, with most experiencing ongoing…
Abstract Number: 2672 • 2015 ACR/ARHP Annual Meeting
Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States
George A. Karpouzas¹, Taylor Draper², Elizabeth Hernandez¹ and Sarah Ormseth¹, ¹Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Psychology, Loma Linda University, Loma Linda, CA
Background/Purpose: Patients and physicians often differ in their perceptions of disease activity in Rheumatoid arthritis (RA) as described by patients' and evaluators' global assessments (PGA…
Abstract Number: 2686 • 2015 ACR/ARHP Annual Meeting
No Clear Association Between the Presence of Ultrasound Synovitis and Patient Reported Outcomes in Rheumatoid Arthritis Patients in Remission
Myrthe van der Ven¹, T. Martijn Kuijper¹, Andreas Gerards², I. Tchetverikov³, A.E.a.M. Weel^1,4, Derkjen van Zeben⁵, Mieke Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ³Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ⁴Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁵Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands
Background/Purpose: Several studies assessed disease activity with ultrasound in rheumatoid arthritis (RA) patients who were in clinical remission. These studies found ultrasound synovitis in 48-73%…
Abstract Number: 2885 • 2015 ACR/ARHP Annual Meeting
Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study
Filip van Den Bosch^1,2, Edit Drescher³, Jan Rosa⁴, Ronald Pedersen⁵, Randi Bonin⁶, Bonnie Vlahos⁷, Jack F Bukowski⁶ and Sameer Kotak⁸, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁴Mediscan Group, Prague, Czech Republic, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁸Global Health and Value, Pfizer, New York, NY
Background/Purpose: In patients with active, NSAID-resistant, non-radiographic axial spondyloarthritis (nr-axSpA) who participated in the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), health-related quality-of-life…
Abstract Number: 430 • 2015 ACR/ARHP Annual Meeting
Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA
Peter C. Taylor¹, Juan J Gomez-Reino², Rieke Alten³, Philippe Bertin⁴, Roberto Caporali⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ³Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, CHU Dupuytren, Limoges, France, ⁵University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: The approach of setting disease activity targets and adjusting therapy appropriately to achieve the target has been proven to optimize outcomes in Rheumatoid Arthritis…
Abstract Number: 2967 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Involvement in SSc Correlates with Poor Short Form 36 and SSc Health Assessment Questionnaire Scores As Well As Lower TNF-Alpha Gene Expression in PBMCs
Eliza Pelrine¹, Marie-Dominique Ah-Kioon¹, Meng Zhang², Franck J. Barrat³, Robert F. Spiera³ and Jessica K. Gordon³, ¹Hospital for Special Surgery, New York, NY, ²Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic Sclerosis (SSc) is characterized by a wide variety of symptoms and disease manifestations including joint pain, gastrointestinal dysfunction, interstitial lung disease, and cardiomyopathy. …
Abstract Number: 651 • 2015 ACR/ARHP Annual Meeting
The Prediction of Long-Term Minimal Disease Activity and Its Benefits in Patients with Psoriatic Arthritis
Philip J. Mease¹, Arthur Kavanaugh², Laura C Coates³, Iain McInnes⁴, Maja Hojnik⁵, Ying Zhang⁶, Jaclyn K. Anderson⁶, Alex Dorr⁶ and Dafna Gladman⁷, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²University of California San Diego, La Jolla, CA, ³Leeds Teaching Hospitals Trust, Leeds, United Kingdom, ⁴University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom, ⁵AbbVie, Ljubljana, Slovenia, ⁶AbbVie, North Chicago, IL, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA)1 is a clinically meaningful and comprehensive treatment target for psoriatic arthritis (PsA). The purpose was to determine if baseline (BL)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].